United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer looks like good value with its vaccine catalyst and dividend yield. PFE stock will be 60% higher within several years after the FDA grants EUA for its Covid-19 vaccine.

Pfizer Looks Like Good Value With Its Vaccine Catalyst and Dividend Yield

Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.

Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate

AstraZeneca

BioNTech SE

Moderna

Positive developments related to coronavirus vaccine candidates have supported stock markets in November. Three leading coronavirus vaccine candidates achieve encouraging efficacy rate.

3 Coronavirus Vaccine Makers Near Finish Line in November

Corning

West Pharmaceutical Services

Even when a coronavirus vaccine is ready, distribution could be a challenge -- but recent innovations in medical glass could benefit the public and investors alike.

The Vaccines Are Almost Ready, but the Challenges Are Only Beginning

Inovio Pharmaceuticals

Novavax

These dark horses are getting their second wind.

3 Long-Shot Coronavirus Vaccine Stocks to Watch in December

Requests for Emergency Use Authorization and formal FDA approvals are next on the agenda.

What to Watch for Next in the Coronavirus Vaccine Race

Should Pfizer Shareholders Sell Their Viatris Stock?

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.

Pfizer/BioNTech Seek Nod for Emergency Use of COVID-19 Vaccine

Antero Resources

PulteGroup

Piper Sandler Cos

Wayfair

Back-to-back positive vaccine updates have offered sweet surprises to Wall Street from the start of the Thanksgiving month this year.

4 Sectors to Prosper in Thanksgiving Week

In light of a collaboration with a major drugmaker and a fast-track toward possible FDA approval, BNTX stock is practically irresistible. The post With Pfizer Partnership, BioNTech Stock Should Push Higher appeared first on InvestorPlace.

With Pfizer Partnership, BioNTech Stock Should Push Higher

Gilead Sciences

Eli Lilly

Regeneron Pharmaceuticals

A COVID-19 vaccine appears to be just around the corner, and many of the companies developing drugs, cocktails, vaccines and treatments are very close to crossing the finish line.

With a Vaccine Coming Soon, Where Do These COVID-19 Stocks Stand?

It isn't as simple as buying stock in the most recent winners.

With 2 Effective Coronavirus Vaccine Candidates, How Should Investors Proceed?

AbbVie

Wells Fargo

The Dividend Stocks screener at GuruFocus finds 616 dividend stocks held by the gurus as of the writing of this article. Another 19 are listed as over-the-counter stocks.

3 Dividend Stocks Gurus Like

The U.K. has ordered 40 million vaccine doses from Pfizer and BioNTech — enough for up to a third of the population.

Decision on approving Pfizer-BioNTech vaccine to be made in ‘shortest time possible,' U.K. regulator says

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors. BASIS is a global Phase 3, open-label, multicenter study that will evaluate annualized bleed rate (ABR) through 12 months on prophylaxis treatment with marstacimab, an investigat

Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors

Americans could start receiving a COVID-19 vaccine as early as 11 December, according to the chief scientific adviser for the US government's vaccine programme.

Americans could start receiving Pfizer vaccine 'as early as 11 December'

Johnson & Johnson

Here are ideas for both conservative and aggressive investors.

Top COVID Vaccine Stocks to Buy Now

Biogen

These three stocks are ready to break out.

3 Best Pharma Stocks to Buy Right Now

Pfizer's coronavirus vaccine candidate comes with two hurdles that might give its competitors an edge.

Why Ultra-Cold Storage and Two-Dose Shots Could Spell A Logistical Nightmare for Pfizer

Dr. Angela Rasmussen explains why news from Pfizer and Moderna's mRNA vaccine trials is so promising.

What This Virus Expert Thinks About mRNA Vaccine Candidates for COVID-19

The group of independent experts will discuss Pfizer's request for emergency use authorization of its coronavirus vaccine candidate.

FDA to Discuss Pfizer's Coronavirus Vaccine Authorization Request in December

More big news for leaders in the coronavirus vaccine race will be on the way soon.

Near-Term Catalysts to Watch for COVID Vaccine Stocks

Here's what a pandemic expert thinks about the recent coronavirus vaccine trial data.

A Doctor Explains: What Pfizer's Big Coronavirus Vaccine News Means

Dr. Leo Nissola explains why these two stocks are both likely winners.

Moderna and Pfizer Investors: There's Room For Multiple mRNA Coronavirus Vaccine Winners

Dr. Angela Rasmussen explains how this new class of vaccines can help prevent COVID-19.

News for Pfizer Stock (PFE)